Alpha-PET for Prostate Cancer: Preclinical investigation using Tb-149-PSMA-617

In this study, it was aimed to investigate Tb-149-PSMA-617 for targeted a-therapy (TAT) using a mouse model of prostate-specific membrane antigen (PSMA)-expressing prostate cancer. Tb-149-PSMA-617 was prepared with >98% radiochemical purity (6 MBq/nmol) for the treatment of mice with PSMA-positive PC-3 PIP tumors. Tb-149-PSMA-617 was applied at 1 x 6 MBq (Day 0) or 2 x 3 MBq (Day 0 & Day 1 or Day 0 & Day 3) and the mice were monitored over time until they had reached a pre-defined endpoint which required euthanasia. The tumor growth was significantly delayed in mice of the treated groups as compared to untreated controls (p < 0.05). TAT was most effective in mice injected with 2 x 3 MBq (Day 0 & 1) resulting in a median lifetime of 36 days, whereas in untreated mice, the median lifetime was only 20 days. Due to the beta(+)-emission of Tb-149, tumor localization was feasible using PET/CT after injection of Tb-149-PSMA-617 (5 MBq). The PET images confirmed the selective accumulation of Tb-149-PSMA-617 in PC-3 PIP tumor xenografts. The unique characteristics of Tb-149 for TAT make this radionuclide of particular interest for future clinical translation, thereby, potentially enabling PET-based imaging to monitor the radioligand's tissue distribution.

Koster, U. (author)
Bernhardt, Peter,1966Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för radiofysik,Institute of Clinical Sciences, Department of Radiation Physics(Swepub:gu)xbernp (author)
Gracheva, N. (author)
Johnston, K. (author)
Schibli, R. (author)
van der Meulen, N. P. (author)
Muller, C. (author)
Göteborgs universitetInstitutionen för kliniska vetenskaper, Avdelningen för radiofysik (creator_code:org_t)

By the author/editor: Umbricht, C. A.; Koster, U.; Bernhardt, Peter ...; Gracheva, N.; Johnston, K.; Schibli, R.; show more...; van der Meulen, ...; Muller, C.; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Medical Biotechn ...; and Biomedical Labor ...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.